Overblog Suivre ce blog
Editer l'article Administration Créer mon blog
12 mars 2011 6 12 /03 /mars /2011 09:52

Clin Microbiol Infect. 2011 Jan 17. doi: 10.1111/j.1469-0691.2011.03459.x. 


High sensitivity and specificity of the C6-peptide ELISA on cerebrospinal fluid in Lyme neuroborreliosis patients.


van Burgel NDBrandenburg AGerritsen HJKroes ACvan Dam AP.) 

 

Department of Medical Microbiology, Centre of Infectious Diseases, Leiden University Medical Centre, Leiden ) IZORE, Centre for Infectious Diseases, Leeuwarden ) Department of Medical Microbiology, OLVG, Amsterdam, The Netherlands.


Clin Microbiol Infect ABSTRACT:

Lyme neuroborreliosis (LNB) is a serious but treatable disease.

The diagnosis of LNB poses a challenge to clinicians, and improved tests are needed.

The C6-peptide ELISA is frequently used on serum but not on cerebrospinal fluid (CSF).

Data on the sensitivity of the C6-peptide ELISA in CSF in patients suffering from LNB have been conflicting.

Serum-CSF pairs from 59 LNB patients, 36 Lyme non-neuroborreliosis cases, 69 infectious meningitis/encephalitis controls and 74 neurological controls were tested in a C6-peptide ELISA.

With the optimal cut-off of 1.1, the sensitivity of the C6-peptide ELISA for LNB patients in CSF was 95%, and the specificity was 83% in the Lyme non-neuroborreliosis patients, 96% in the infectious controls, and 97% in the neurological controls.

These results suggest that the C6-peptide ELISA has a high sensitivity and good specificity for the diagnosis of LNB patients in CSF.

The C6-peptide ELISA can be used on CSF in a clinical setting to screen for LNB.


© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

PMID: 21375653 [PubMed - as supplied by publisher]

Partager cet article

Repost 0
Published by chronimed - dans Concept
commenter cet article

commentaires